Genzyme MS Drug Gets Good Results
French drug maker Sanofi-Aventis said a phase-three study of the multiple sclerosis drug alemtuzumab, developed by Genzyme, has had positive results.
Sanofi acquired Genzyme, which has substantial operations in the MetroWest area, in April.
Sanofi said the study was the first of two randomized phase-three clinical trials comparing the drug to an existing MS treatment, Rebif. The two-year study found that patients receiving alemtuzumab were 55 percent less likely to relapse than those using Rebif, Sanofi said.
The study did not find that alemtuzumab had statistically significant advantages over Rebif when it came to patients' likelihood of becoming more disabled.
The second phase-three trial is under way and should produce results by the fourth quarter of 2011, Sanofi said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments